1. |
Jiao Q, Bi L, Ren Y, et al. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer, 2018, 17(1): 36.
|
2. |
Drake JM, Lee JK, Witte ON. Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer. Mol Cell Biol, 2014, 34(10): 1722-1732.
|
3. |
Hartmann JT, Haap M, Kopp HG, et al. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab, 2009, 10(5): 470-481.
|
4. |
Longo VD, Mattson MP. Fasting: molecular mechanisms and clinical applications. Cell Metab, 2014, 19(2): 181-192.
|
5. |
Fujita KI, Ishida H, Kubota Y, et al. Toxicities of receptor tyrosine kinase inhibitors in cancer pharmacotherapy: management with clinical pharmacology. Curr Drug Metab, 2017, 18(3): 186-198.
|
6. |
Hamnvik OP, Choueiri TK, Turchin A, et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer, 2015, 121(2): 311-319.
|
7. |
Petrelli F, Borgonovo K, Cabiddu M, et al. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer, 2012, 78(1): 8-15.
|
8. |
Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase Ⅲ trial. J Clin Oncol, 2013, 31(30): 3791-3799.
|
9. |
Park SE, Lee SH, Ahn JS, et al. Increased response rates to salvage chemotherapy administered after PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer. J Thorac Oncol, 2018, 13(1): 106-111.
|
10. |
Symonds RP, Gourley C, Davidson S, et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol, 2015, 16(15): 1515-1524.
|
11. |
Thornton K, Kim G, Maher VE, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U. S. Food and Drug Administration drug approval summary. Clin Cancer Res, 2012, 18(14): 3722-3730.
|
12. |
Qin S, Li Q, Gu S, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol, 2021, 6(7): 559-568.
|
13. |
Gross-Goupil M, Kwon TG, Eto M, et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase Ⅲ, randomized ATLAS trial. Ann Oncol, 2018, 29(12): 2371-2378.
|
14. |
Besse B, Mazières J, Ribassin-Majed L, et al. Pazopanib or placebo in completely resected stage Ⅰ NSCLC patients: results of the phase Ⅱ IFCT-0703 trial. Ann Oncol, 2017, 28(5): 1078-1083.
|
15. |
Blay JY, Serrano C, Heinrich MC, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol, 2020, 21(7): 923-934.
|
16. |
Chi Y, Shu Y, Ba Y, et al. Anlotinib monotherapy for refractory metastatic colorectal cancer: a double-blinded, placebo-controlled, randomized phase Ⅲ trial (ALTER0703). Oncologist, 2021, 26(10): e1693-e1703.
|
17. |
Ellis PM, Shepherd FA, Millward M, et al. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR. 26): a double-blind, randomised, phase 3 trial. Lancet Oncol, 2014, 15(12): 1379-1388.
|
18. |
du Bois A, Floquet A, Kim JW, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol, 2014, 32(30): 3374-3382.
|
19. |
Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 2017, 18(12): 1688-1700.
|
20. |
Grávalos C, Carrato A, Tobeña M, et al. A randomized phase Ⅱ study of axitinib as maintenance therapy after first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer, 2018, 17(2): e323-e329.
|
21. |
Machiels JP, Bossi P, Menis J, et al. Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN). Ann Oncol, 2018, 29(4): 985-991.
|
22. |
Kazandjian D, Blumenthal GM, Yuan W, et al. FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer. Clin Cancer Res, 2016, 22(6): 1307-1312.
|
23. |
Langerbeins P, Bahlo J, Rhein C, et al. The CLL12 trial protocol: a placebo-controlled double-blind Phase Ⅲ study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. Future Oncol, 2015, 11(13): 1895-1903.
|
24. |
Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase Ⅲ trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol, 2016, 34(13): 1448-1454.
|
25. |
Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med, 2015, 372(7): 621-630.
|
26. |
Brose MS, Robinson BG, Sherman SI, et al. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. Cancer, 2022, 128(24): 4203-4212.
|
27. |
Iacovelli R, Massari F, Albiges L, et al. Evidence and clinical relevance of tumor flare in patients who discontinue tyrosine kinase inhibitors for treatment of metastatic renal cell carcinoma. Eur Urol, 2015, 68(1): 154-160.
|
28. |
Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res, 2002, 62(24): 7284-7290.
|
29. |
Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res, 2002, 62(16): 4645-4655.
|
30. |
杨毅, 陈江华. 分子靶向药物与肾脏损伤的研究进展. 现代实用医学, 2020, 32(12): 1443-1445.
|
31. |
Boye M, Wang X, Srimuninnimit V, et al. First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in east Asian never-smoker patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer: quality of life results from a randomized phase Ⅲ trial. Clin Lung Cancer, 2016, 17(2): 150-160.
|
32. |
Zhao Y, Liu J, Cai X, et al. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. BMJ, 2019, 367: l5460.
|
33. |
Zhang Z, Zeng K, Zhao S, et al. Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis. Ther Adv Med Oncol, 2019, 11: 1758835919891652.
|
34. |
Kumasaka R, Nakamura N, Shirato K, et al. Side effects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy. J Clin Oncol, 2004, 22(12): 2504-2505.
|
35. |
Maruyama K, Chinda J, Kuroshima T, et al. Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib. Intern Med, 2015, 54(7): 823-826.
|
36. |
Tang J, Liu N, Zhuang S. Role of epidermal growth factor receptor in acute and chronic kidney injury. Kidney Int, 2013, 83(5): 804-810.
|
37. |
Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med, 2009, 122(4): 322-328.
|
38. |
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med, 2003, 9(6): 669-676.
|
39. |
Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol, 2018, 11(1): 120.
|
40. |
Sahade M, Caparelli F, Hoff PM. Cediranib: a VEGF receptor tyrosine kinase inhibitor. Future Oncol, 2012, 8(7): 775-781.
|
41. |
Dhillon S. Ripretinib: First approval. Drugs, 2020, 80(11): 1133-1138.
|
42. |
Piscitani L, Sirolli V, Di Liberato L, et al. Nephrotoxicity associated with novel anticancer agents (aflibercept, dasatinib, nivolumab): case series and nephrological considerations. Int J Mol Sci, 2020, 21(14): 4878.
|